A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01539512 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Idelalisib
DRUG: Rituximab
DRUG: Placebo to match idelalisib

Sponsor

Gilead Sciences